Preparing for next pandemic, Korea's SK pumps $261M into vaccine R&D site

SK bioscience has taken a look at the receding COVID-19 vaccine market and its own stuttering effort to win market share and decided to double down, outlining plans to invest $261 million in a R&D hub designed to establish it as a leading force in the global response to new infectious diseases.